On Tuesday, Progyny hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before.
IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the best-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a chart pattern and break out.
Earnings grew 31% last quarter, up from 5% in the prior report. Revenue also increased, from 2% to 11%.
Progyny holds the No. 3 rank among its peers in the Medical-Services industry group. Option Care Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
